
|Videos|October 23, 2017
Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma
Author(s)Celeste Lebbe, MD, PhD
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
Advertisement
Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.
In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.
The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































